Author: healthprofessionalradio

Alison Miles, a patient living with Pompe disease, a condition that develops when the body can’t make a protein that breaks down a complex sugar, glycogen, shares her unique diagnosis journey, the importance of self-education and patient empowerment, and the company she started, due to her mobility issues, for functional socks with grips that were fashionable.  She discusses her experience with Nexviazyme® (avalglucosidase alfa) as a patient in the COMET clinical trial.

Dr. Devon Christie, MD, is the Medical and Therapeutic Services Director with Numinus Wellness Inc., a Canadian-based company at the forefront of advancing safe, effective and innovative psychedelic-assisted therapies, and a clinical instructor with the UBC Department of Medicine, shares some insights about the therapy and why the U.S. should consider this type of therapy for those who medically qualify and what others can learn from some of Canada’s recent developments. 

Abizer Gaslightwala, Vice President, Head of U.S. Hematology and Oncology at Jazz Pharmaceuticals, discusses the “Nothing Small About It” online program developed with leading cancer organizations focused exclusively on the psychosocial and emotional needs of the small cell lung cancer (SCLC) community. By creating the first and only digital hub focused exclusively on SCLC, Jazz and partners aim to inspire those living with this aggressive disease to take an active role in their health and well-being. 

Dr. Jared Silver, MD, PhD, Allergist Immunologist & Indication Lead for Mepolizumab, US Medical Affairs Respiratory at GSK discusses the recent FDA approval of NUCALA (mepolizumab) as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids. He explains why incorporating a biologic can be an important part of a patient’s treatment plan. 

Dr. Lisa Anderson, CEO, President and co-founder of Paragonix Technologies, Inc., a company delivering a new standard in organ preservation and transport, discusses a new research study called GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs) to look at lung preservation and how the way the organ is preserved and transported impact the success of the transplant. 

Shannon Resetich, Global Franchise Head, Rare Diseases at Sanofi Genzyme discusses the company’s Humanitarian Aid Program started 30 years ago. The program is largely focused on patients with lysosomal storage disorder (LSDs) diseases who need enzyme replacement therapies. She talks about how this humanitarian program helps to ensure patients with LSDs have access to treatment no matter where they are located or what they can afford. She also discusses how the program works effectively, the partnerships they have forged and the support that the program provides to elevate the standards for rare disease care in the communities around the world. She shares Sanofi Genzyme’s vision moving forward and why this type of program is so essential and should be part of a pharmaceutical company’s mission. 

Pain Awareness Month is September and Dr. Alan Rechter, MD, an orthopedic surgeon, from Orthopoedic Associates in Houston, TX, discusses the newest method of effectively managing postoperative pain without opiods. He will explain why this latest development is such an important step in helping patients who are undergoing a variety of procedures.

Carla Mack, Global Head of Professional Affairs at Alcon discusses the company’s latest innovation, TOTAL30®, the first-and-only monthly replacement, water gradient contact lens that feels like nothing even at day 30. This lens offers a new solution to the ‘say nothing’ patients and helps to better retain more contact lens wearers. 

August is Spinal Muscular Atrophy (SMA) Awareness Month, and this year (2021) also marks the first anniversary of the FDA approval of Evrysdi (risdiplan) to treat SMA in adults and children two months and older. Here to talk about how this treatment has improved patient’s lives is Eric Arnold, a 35 year old lawyer in West Virginia who is grateful for the new treatments available to SMA patients and its transformative impact. He is joined by Dr. Karen Chen, CEO of the Spinal Muscular Atrophy Foundation who offers insights into this rare and debilitating disease and the current treatment landscape.

Michael Frank, CEO and Chairman of Revive Therapeutics discusses the Phase 3 trial of Bucillamine, a well known prescribed anti-inflammatory drug in Japan and South Korea, as an oral at-home pill treatment option for mild-moderate to severe COVID-19.